Caffeine in saliva after peroral intake: Early sample collection as a possible source of error

Therapeutic Drug Monitoring

Volumn 19, Issue 5, 1997, Pages 521-524

  Biederbick, Walter ^a   Joseph, Gerhard ^a   Rump, Alexis ^b   Theisohn, Martin ^a   Klaus, Wolfgang ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Department of Pharmacology ^*

Author keywords

Caffeine; HPLC; Saliva; Salivary glands; Therapeutic drug monitoring

Indexed keywords

CAFFEINE;

ADULT; ARTICLE; CONTAMINATION; DIAGNOSTIC ERROR; DRUG MONITORING; DRUG SALIVA LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; CAFFEINE; DRUG MONITORING; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; SALIVA; SALIVARY GLANDS; TIME FACTORS;

EID: 0031423876     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199710000-00006     Document Type: Article

References (16)

1. Aranda JV, Grondin D, Sasyniuk B. Pharmacologic considerations in the therapy of neonatal apnea. Pediatr Clin North Am 1981;28: 113-33.
2. Murat U, Moriette G, Blin MC, et al. The efficacy of caffeine in the treatment of recurrent idiopathic apnoea in premature infants. J Pediatr 1981;99:884-9.
3. Scanlon JEM, Chin KC, Morgan MEI, et al. Caffeine or theophylline for neonatal apnoea? Arch Dis Child 1992;67:425-8.
4. Hale TW, Shum S, Habersang R. Therapeutic drug monitoring in a pediatric laboratory. Dev Pharmacol Ther 1987;10:81-9.
5. Somani SM, Khanna NN. Methylxanthines in serum, saliva, and spinal fluid of premature infants. Semin Perinatol 1981;4:346-50.
6. Suzuki Y, Uematsu T, Mizuno A, et al. Determination of caffeine in saliva by high-performance liquid chromatography: new sampling method for saliva using filter paper. Ther Drug Monit 1989; 16:88-92.
7. Soto J, Sacristan JA, Alsar MJ. Cerebrospinal fluid concentrations of caffeine following oral drug administration: correlation with salivary and plasma concentrations. Ther Drug Monit 1994;16: 108-10.
8. Renner E, Wietholtz H, Huguenin PH, et al. Caffeine: a model compound for measuring liver function. Hepatology 1984;4:38-46.
9. Fuhr U, Molz KH. The plasma ratio paraxanthine/caffeine after a caffeine test dose in patients with impaired liver function [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1995;351:R2.
10. Setchell KDR, Welsh MB, Klooster MJ, et al. Rapid high-performance liquid chromatography assay for salivary and serum caffeine following an oral load: an indicator of liver function. J Chromatogr 1987;385:267-74.
11. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva. Pharmacogenetics 1994;4:109-16.
12. Baker A, Girling A, Worthington D, et al. The prognostic significance of caffeine half-life in saliva in children with chronic liver disease. J Pediatr Gastroenterol Nutr 1995;20:196-201.
13. Zylber-Katz E, Granit L, Levy M. Relationship between caffeine concentrations in plasma and saliva. Clin Pharmacol Ther 1984; 36:133-7.
14. Khanna NN, Bada HS, Somani SM. Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants. J Paediatr 1980;96:494-9.
15. Hildebrandt R, Gundert-Remy V, Weber E. Transfer of caffeine to breastmilk [abstract]. Br J Clin Pharmacol 1983;15:612.
16. Alkaysi HN, Shiekh Salem M El-Sayed YM. High performance liquid Chromatographic analysis of caffeine concentrations in plasma and saliva. J Clin Pharm Ther 1988;13:109-15.